Treatment Information

Back

Liver Cancer treatment details. Chemotherapy, Biologic therapy.

Chiba University, Chiba, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:5City/State/Province:Chiba
Treatments:Chemotherapy, Biologic therapyHospital:Chiba University
Drugs:Journal:Link
Date:Mar 2014

Description:

Patients:
This phase 2 study involved 26 advanced hepatocellular carcinoma patients with an average age of 65.5 years; 88.5% were male.

Treatment:
Patients were treated with the chemotherapy agent S-1 and the biologic agent sorafenib.

Toxicities:
There was one sudden death that may have been related to treatment. Grade 4 low blood sodium and grade 3 liver toxicity and thrombocytopenia were also reported.

Results:
The median overall survival was 10.5 months.

Support:
One of this study’s authors has received funding from Bayer Pharmaceuticals.

Correspondence: Dr. Tetsuhiro Chiba; email: [email protected]



Back